BioSpace News Archive

Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), today announced the promotions of Joe Shulman to Chief Technical Officer, Patrick Kleyn, Ph.D., to Senior Vice President and Head of Translational Research and Development, and Elisabeth Crönert-Bendell, M.D., to Senior Vice President and Head of Strategy.

Entrada Therapeutics, Inc., a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle therapeutics as a new class of medicines, announced that Dipal Doshi, President and Chief Executive Officer, will participate on the Neuromuscular Panel at the Cowen 42nd Annual Health Care Conference.

Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that it will report fourth quarter and full year 2021 financial results and provide a corporate update before market open on Wednesday, March 2, 2022.

NeoGenomics, Inc. today announced fourth quarter and full year 2021 results for the period ended December 31, 2021.

Science 37 Holdings, Inc. (Nasdaq: SNCE), the Agile Clinical Trial Operating System™, today announced the company will be participating in the upcoming Cowen 42nd Annual Health Care Conference.

ChromaCode, Inc. announced today that the U.S. Food and Drug Administration has expanded the Emergency Use Authorization of ChromaCode’s HDPCR SARS-CoV-2 Assay to include several new qPCR instruments and use of 384-well plates.

Recce Pharmaceuticals Ltd (ASX:RCE, FSE:R9Q) (the Company), the Company developing new classes of synthetic anti-infectives, is pleased to report the final three subjects of cohort three at 500mg have been intravenously dosed in the Phase I intravenous (IV) clinical trial of RECCE® 327 (R327), indicating a good safety and tolerability profile among 10 healthy male subjects.

BrainsWay Ltd. today announced the publication of results in the Journal of Clinical Medicine further defining the efficacy of the Company’s proprietary Deep TMS™ symptoms.

Rani Therapeutics Holdings, Inc. today announced the development of a high-capacity oral biologics device known as the RaniPill™ HC (High Capacity), capable of delivering up to a 500%-plus higher drug payload than Rani’s existing oral biologics capsule.

hC Bioscience, Inc., a drug discovery and development company focused on first-in-class tRNA-based therapeutics targeting protein dysfunction, has closed a Series A financing of $24 million led by a strong syndicate of investors, including ARCH Venture Partners, Takeda Ventures and 8VC.